Clinical development costs are rising due to the disruption of shipping routes in the Strait of Hormuz, writes Mathini ...

Novo Nordisks Aleksandar Ciric writes that leaders can apply sports principles such as speed of action, clarity, and ...

Speed to market wont guarantee success in todays launch environment. Anticipating what prescribers, patients and payers will ...

On this week's episode of the Business of Biotech, Thijs Spoor, CEO at Perspective Therapeutics, a company developing Pb 212 (lead)-based therapeutics, talks about why radiopharmaceuticals are surging ...

First-in-human oncology trials are often described as flexible, yet many of the most consequential choices made early on quietly narrow future options. Initial dose selection and escalation strategies ...

On this week's episode of the Business of Biotech, Dan McHugh, head of the investment team at Yosemite, explains the San Francisco VC group's approach to investing in early-stage cancer therapeutics ...

For pharma leaders, the critical question is no longer if the AI works, but what behavior it's promoting. Efficiency is table stakes; behavioral governance is the new competitive advantage. Every ...

On this week's episode of the Business of Biotech we're speaking with Alan Bash, President, Carvykti, at Legend Biotech, about how Carvykti became a blockbuster, category-leading CAR T therapy for ...